
BioCryst Pharmaceuticals (BCRX) Stock Forecast & Price Target
BioCryst Pharmaceuticals (BCRX) Analyst Ratings
Bulls say
BioCryst Pharma is attractive because 3Q26 revenue of $180M and non-GAAP operating profit of $53M both topped consensus, while cash and equivalents of $376M support continued pipeline execution. Orladeyo remains durable despite new HAE prophylaxis competition, with $175M in 3Q26 sales, unchanged FY26 guidance of $625M-$645M, and a pediatric pellet launch that adds an incremental growth channel with 47 prescriptions already on a YTD basis. The outlook is further strengthened by multiple catalysts, including BCX17725 top-line results by YE26 and navenibart data expected in 3Q27, which could reinforce BioCryst’s positioning in hereditary angioedema and expand the market opportunity.
Bears say
BioCryst Pharma is pressured by a high-risk development profile in which regulators may demand additional data, extend study timelines, or limit label breadth, any of which could weaken commercialization prospects. Its outlook is further constrained by intense competition in hereditary angioedema from Takhzyro and CSL Behring, with additional earlier-stage threats from Pharvaris and Intellia Therapeutics, while deucrictibant’s results were only broadly confirmatory and may still face resistance from patients already doing well on Orladeyo. Financially, the company may need additional external funding to advance its platform, and any inability to access capital markets could delay or terminate development campaigns.
This aggregate rating is based on analysts' research of BioCryst Pharmaceuticals and is not a guaranteed prediction by Public.com or investment advice.
BioCryst Pharmaceuticals (BCRX) Analyst Forecast & Price Prediction
Start investing in BioCryst Pharmaceuticals (BCRX)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About BioCryst Pharmaceuticals (BCRX) Forecast
BioCryst Pharmaceuticals (BCRX) Analyst Forecast & Price Prediction
Start investing in BioCryst Pharmaceuticals (BCRX)
Order type
Buy in
Order amount
Est. shares
0 shares